CN114502553B - 作为第iii型受体酪氨酸激酶抑制剂之杂环吡唑衍生物 - Google Patents
作为第iii型受体酪氨酸激酶抑制剂之杂环吡唑衍生物 Download PDFInfo
- Publication number
- CN114502553B CN114502553B CN202080059010.6A CN202080059010A CN114502553B CN 114502553 B CN114502553 B CN 114502553B CN 202080059010 A CN202080059010 A CN 202080059010A CN 114502553 B CN114502553 B CN 114502553B
- Authority
- CN
- China
- Prior art keywords
- methyl
- cyclopenta
- dihydrothieno
- indazol
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891097P | 2019-08-23 | 2019-08-23 | |
| US62/891,097 | 2019-08-23 | ||
| PCT/US2020/047552 WO2021041276A1 (en) | 2019-08-23 | 2020-08-22 | Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114502553A CN114502553A (zh) | 2022-05-13 |
| CN114502553B true CN114502553B (zh) | 2024-07-26 |
Family
ID=74685735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080059010.6A Active CN114502553B (zh) | 2019-08-23 | 2020-08-22 | 作为第iii型受体酪氨酸激酶抑制剂之杂环吡唑衍生物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12448394B2 (https=) |
| EP (1) | EP4017853A4 (https=) |
| JP (1) | JP7651557B2 (https=) |
| KR (1) | KR20220051365A (https=) |
| CN (1) | CN114502553B (https=) |
| AU (1) | AU2020337883B2 (https=) |
| BR (1) | BR112022003383A2 (https=) |
| CA (1) | CA3151821A1 (https=) |
| MX (1) | MX2022002062A (https=) |
| TW (1) | TWI759829B (https=) |
| WO (1) | WO2021041276A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130274255A1 (en) * | 2012-04-12 | 2013-10-17 | Development Center For Biotechnology | Heterocyclic pyrazole compounds, method for preparing the same and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2323952T3 (es) | 2002-05-15 | 2009-07-28 | Janssen Pharmaceutica Nv | 3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg. |
| RU2425677C2 (ru) | 2005-01-21 | 2011-08-10 | Астекс Терапьютикс Лимитед | Соединения, предназначенные для использования в фармацевтике |
| CN101146532B (zh) | 2005-01-21 | 2012-05-09 | 阿斯泰克斯治疗有限公司 | 药物化合物 |
| JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体 |
| JP2010505859A (ja) | 2006-10-06 | 2010-02-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤およびそれを使用するための方法 |
| KR101122481B1 (ko) | 2007-05-04 | 2012-02-29 | 아이알엠 엘엘씨 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물 |
| EA024729B1 (ru) * | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| UA112425C2 (uk) | 2010-12-13 | 2016-09-12 | Еррей Біофарма Інк. | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
| US8877763B2 (en) * | 2012-03-22 | 2014-11-04 | Genosco | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| MX2018006856A (es) | 2015-12-07 | 2018-08-01 | Plexxikon Inc | Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos. |
-
2020
- 2020-08-21 TW TW109128678A patent/TWI759829B/zh active
- 2020-08-22 BR BR112022003383A patent/BR112022003383A2/pt unknown
- 2020-08-22 CN CN202080059010.6A patent/CN114502553B/zh active Active
- 2020-08-22 MX MX2022002062A patent/MX2022002062A/es unknown
- 2020-08-22 EP EP20856905.3A patent/EP4017853A4/en active Pending
- 2020-08-22 KR KR1020227009059A patent/KR20220051365A/ko active Pending
- 2020-08-22 AU AU2020337883A patent/AU2020337883B2/en active Active
- 2020-08-22 WO PCT/US2020/047552 patent/WO2021041276A1/en not_active Ceased
- 2020-08-22 JP JP2022511322A patent/JP7651557B2/ja active Active
- 2020-08-22 US US17/636,116 patent/US12448394B2/en active Active
- 2020-08-22 CA CA3151821A patent/CA3151821A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130274255A1 (en) * | 2012-04-12 | 2013-10-17 | Development Center For Biotechnology | Heterocyclic pyrazole compounds, method for preparing the same and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022545019A (ja) | 2022-10-24 |
| WO2021041276A1 (en) | 2021-03-04 |
| US12448394B2 (en) | 2025-10-21 |
| US20220289759A1 (en) | 2022-09-15 |
| CA3151821A1 (en) | 2021-03-04 |
| AU2020337883B2 (en) | 2025-08-28 |
| EP4017853A4 (en) | 2023-08-30 |
| BR112022003383A2 (pt) | 2022-05-17 |
| CN114502553A (zh) | 2022-05-13 |
| TW202115087A (zh) | 2021-04-16 |
| JP7651557B2 (ja) | 2025-03-26 |
| TWI759829B (zh) | 2022-04-01 |
| AU2020337883A1 (en) | 2022-03-24 |
| EP4017853A1 (en) | 2022-06-29 |
| KR20220051365A (ko) | 2022-04-26 |
| MX2022002062A (es) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5452811B2 (ja) | 有糸分裂進行を阻害するための化合物 | |
| TWI434848B (zh) | Ｊａｋ２抑制劑及其用於治療骨髓增生性疾病及癌症之用途 | |
| CN111646995B (zh) | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 | |
| CN102712625B (zh) | 含氮杂芳基衍生物 | |
| JP7206188B2 (ja) | Ｉｉｉ型受容体チロシンキナーゼ阻害剤としてのキノキサリン化合物 | |
| MXPA06004194A (es) | Inhibicion de fgfr3 y tratamiento de mieloma multiple. | |
| JP5518902B2 (ja) | ヘテロアリール置換ピリダジノン誘導体 | |
| CN114502553B (zh) | 作为第iii型受体酪氨酸激酶抑制剂之杂环吡唑衍生物 | |
| CN115485274A (zh) | 包含噻唑衍生物或其药学上可接受的盐的用于预防或治疗癌症的药物组合物 | |
| RU2833004C2 (ru) | Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III | |
| JP2020536077A (ja) | Ｃｄｋ８／ｃｄｋ１９阻害剤としての新規な［１，６］ナフチリジン化合物及び誘導体 | |
| WO2023008577A1 (ja) | Ｒａｓ／Ｒａｆ結合阻害化合物 | |
| HK40012508A (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors | |
| HK40012508B (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors | |
| KR20250154499A (ko) | Parp 억제제로서의 치환된 질소-함유 트리시클릭 화합물 및 이의 용도 | |
| HK40118749A (zh) | 作为pi3k抑制剂的苯并嘧啶-4(3h)-酮 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |